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It is now well accepted that macrophages are implicated as important cells not only 
in resistance to tumor cells  and infection but also in the immune system as effector 
and  regulatory cells  (1).  Metabolic  functions of macrophages differ  depending  on 
whether they are activated by Bacillus Calmette-Gufrin (BCG), pyran copolymer, or 
Co~ynebacterium parvum, or  elicited  by injection  with  thioglycollate  medium  (TGC), 
proteose-peptone  (PP),  or mineral  oil  (2).  Thus,  activated  or elicited  macrophages 
were shown to secrete lysozomal enzymes (3), plasminogen activator (4), collagenase 
(5), and hydrogen peroxide (6). 
In  contrast  to  the  extensive  studies  on  their  functions,  little  is  known  about 
membrane characteristics  of activated,  elicited,  or resident  macrophages. Although 
several  studies  have  indicated  that  Mac-1,2,3  (7,  8),  F4/80  (9,  10), and  2.6  (11) 
monoclonal antibodies defined macrophage cell surface markers, none of these mon- 
oclonal antibodies have been able to discriminate activated macrophages from elicited 
or  resident  macrophages.  The  only  report  of such  a  selective  antibody was  from 
Kaplan  and  his associates  (12,  13), who produced a  heterologous rabbit  antiserum 
against the P388D1 mouse macrophage cell line that, after very extensive absorptions 
with  the  proper  cells,  detected  a  cell  surface  antigen  (AM~CSA)  associated  with 
activated macrophages induced by pyran or C. parvum. 
To understand precise mechanisms by which macrophages become activated, we 
attempted to produce a series  of monoclonal antibodies specific for activated macro- 
phages.  In  this  report,  we  describe  successful  production  of such  a  monoclonal 
antibody specific for activated tumoricidal macrophages. This monoclonal antibody 
should  provide  a  useful  tool  for  the  analysis  of  activation  or  differentiation  of 
macrophages. 
Materials and Methods 
Animals.  C3H/HeN mice and LOU/CN rats were kindly provided by Dr. R. B. Herberman, 
Biological Development Branch, National Cancer Institute Frederick Cancer Research Facility, 
and bled  in  our facility.  BALB/c mice were purchased  from  Shizuoka  Animal Laboratory 
Center,  Shizuoka, Japan. 
Reagents.  Pyran copolymer (NCS 46015, Hercules Research Center,  Wilmington,  DE) and 
C. parvum (lot CA77 l/B, Wellcome Research Laboratories,  Beckengham, England)  were kindly 
obtained  from  Dr.  H.  T.  Holden,  Biological Development  Branch,  NCI-FCRF. Pyran was 
dissolved in sterile 0.9% NaCI solution, and the pH was adjusted  to 7.2 with  I N NaOH. PP 
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and TGC were purchased from Difco Laboratories, Detroit, MI. Mineral oil was obtained from 
Aldrich Chemical Co., Milwaukee, WI. 
Cell Preparation.  Peritoneal exudate cells (PEC) were obtained from the peritoneal cavity of 
mice treated with TGC or PP (1 ml/mouse of a  10% solution, day -4), pyran (25 mg/kg of 
body weight, day -8) or C. parvum (2.1 mg/mouse, day -8). To obtain purified macrophages, 
PEC were incubated in petri dishes (100  ×  15 mm) for  1-3 h  at 37°C, and adherent cells 
(macrophages) were obtained from the plates by gently scraping with a rubber policeman after 
removing nonadherent cells. For the preparation of neutrophils, mice were treated intraperi- 
toneally with TGC (-18 h) and peritoneal exudate cells were harvested. Blood monocytes were 
purified from peripheral blood by adherence. 
Cell Fusion.  Immune spleen cells from LOU/CN rats primed with two injections of pyran- 
activated PEC from C3H/HeN or BALB/c mice were fused with the P3 ×  63AgSU1  (P3U1) 
mouse myeloma cells  as described previously (14,  15). Screening for a  hybridoma secreting 
a  monoclonal antibody specific  for  activated macrophages was by a  125I-labeled protein, a 
binding assay on pyran-activated macrophages,  or TGC-elicited macrophages.  Hybridoma 
with appropriate characteristics was cloned twice by the limiting dilution method and then 
used for the present study. 
Binding  Assay.  The  cells  (2-5  ×  105  cells  in  50  /~1  of phosphate-buffered  saline  [PBS] 
containing 2% bovine serum albumin [BSA] and I0 mM NaNs) were first incubated for 2-3 h 
at 4°C with 50 #1 of hybridoma supernatant in microtest plates, washed in PBS containing  2% 
BSA and 10 mM NaNz, followed by incubation for 4-6 h with 12SI-labeled protein A (30,000- 
100,000 cpm/well) at 4°C. After incubation, the cells were washed twice, and the radioactivity 
of l~6I-labeled protein A bound to cell surfaces was counted by a gamma counter. 
Purification of  AcM. 1 Monoclonal Antibody and Preparation of Biotinyl-AcM. 1 Antibody.  Supernatant 
from AcM.1 tissue culture was concentrated 10-fold with an Amicon concentrator under the 
nitrogen pressure. Then, concentrated supernatants were  applied on an affinity column of 
protein  A-Sepharose  4B  (Pharmaeia  Fine Chemicals,  Uppsala,  Sweden).  Biotinylation of 
purified AcM.1 antibody was carried out by the method of Bayes and Wilchek (16). 
Fluorescence Study.  Aliquots of 1-3 ×  106 cells to be stained were pelleted by centrifugation 
and incubated with  10-20 pl of biotinylated AcM.1  antibody (1  mg/ml) for 30 rain on ice. 
After washing with 10 ml of cold PBS containing 0.5% BSA and 10 mM NaNs, the cells were 
resuspended in 10-20/~1 of fluorescein isothiocyanate (FITC)-conjugated avidin (FITC-avidin, 
1 mg/ml, E. Y. Laboratories, Inc., San Mateo, CA), and the mixture was further incubated for 
20 min on ice. After washings, the cells were examined with a Zeiss fluorescence microscope 
(Carl Zeiss, Inc., New York).  Cytofluorometry was performed with the EPICS V  cell sorter 
(Coulter Electronics Inc., Hialeah, FL), using appropriate scatter windows to screen out cellular 
debris,  dead  cells,  and  cell  aggregates  (laser  power,  800  mW;  fluorescence gain  20;  and 
photomultiplier, 750-800 V). 
Treatment of Cells with Antibodies and Complement.  Cells were treated with AcM. 1 monoclonal 
antibody (1:1) or with anti-Thy 1 monoclonal antibody (1:400,  clone F7D5, Olac  1976 Ltd, 
Shawa  Farm,  Blackthorn  Bicester Oxon,  OX60  OTP,  England)  for  30  min on  ice.  After 
centrifugation, the cells were suspended in rabbit complement (C) diluted 1:8, and the mixture 
was incubated for another 30 min at 37°C. 
Macrophage-mediated  Cytotoxicity.  Macrophage-mediated  cytotoxicity  was  assessed  as  de- 
scribed previously (17). Target cells were labeled with 100-200 #Ci of sodium Sachromate  (New 
England Nuclear, Boston, MA) for 60 min at 37°C, washed three times, and then added to 
effector  cells at 5 ×  10  ~ cells/well. After 18 h of incubation, the plates were centrifuged for 10 
rain at 350 g, 0.1  ml of supernatant was harvested, and the radioactivity was counted in a 
gamma counter. The percent of specific cytotoxicity was calculated as:  ([cpm in experimental 
group -  cpm with thymocyte control]/[total cpm incorporated into target cells -  cpm with 
thymocyte control])  ×  100. The  baseline control  release of the  target  cells  cultured with 
thymocytes for 18 h varied between 20.3 and 31.6% of the total radioactivity incorporated. 
Results and Discussion 
From  approximately  600  hybrids  obtained  from  four  separate  experiments,  in 
which  immune spleen cells from  LOU/CN  rats  treated with multiple injections of 
pyran-activated PEC of C3H/HeN or BALB/c mice were fused with the P3U1 mouse 1288  TANIYAMA AND  WATANABE  BRIEF DEFINITIVE REPORT 
TABLE I 
Reactivity of a Monoclonal  Antibody (AcM. 1) with Mouse Primary Cells 
Percent of cell types in  Percent 
preparations  AcM. 1  Percent 
Cell preparations  positive  killed ± SE 
Macro-  Lympho-  Neutro-  ± SE 
phages  cytes  phils 
Resident PEC  65  30  5  <5  <5 
TGC-PEC  (day 4)  80  10  10  <5  <5 
Proteose-peptone-PEC (day 4)  74  18  8  <5  <5 
Pyran-PEC  (day 8)  75  18  7  73 ± 4  68 + 3 
C. parvum-PEC (day 8)  77  9  14  62 ± 5  60 ± 5 
TGC-PEC  (18 h)  25  10  65  <5  NDII 
Blood monocytes  95  5  0  <5  ND 
Spleen cells  10  90  0  <5  <5 
Bone marrow cells  --][  --  --  <5  ND 
Thymocytes  5  95  0  <5  <5 
* Stained by Wright-Giemsa method. 
:~ Determined by fluorescence microscopy and cytofluorometry. 
§ Cytotoxicity at 1:2 dilution of AcM. 1 antibody plus C was determined by a dye exclusion test. 
II Not done. 
myeloma cells, we obtained only one stable clone secreting a  monoclonal antibody, 
termed AcM. 1, specific for pyran-activated macrophages but not TGC-elicited mac- 
rophages  (mff),  cloned  twice  and  used  for  the  present  study.  The  isotype  of  the 
antibody was IgG2¢ and it had the capacity to fix C. 
The specificity of the AcM. 1 monoclonal antibody was determined by fluorescence 
microscopy, ~25I-labeled protein A-binding assay, and C-dependent  cytotoxicity. As 
shown  in Table I, the AcM.1  monoclonal  antibody reacted only with  pyran- or  C. 
parvum-activated PEC, but not with TGC-, or PP-elicited PEC, resident PEC, blood 
monocytes,  neutrophils,  spleen  cells,  bone  marrow  cells,  or  thymocytes.  Although 
these  results suggested  that  this  AcM. 1 antibody was  specific for  activated macro- 
phages,  we  further  tested  the  reactivity of the  AcM. 1  antibody  by  using  purified 
macrophages  (>95%  nonspecific esterase-positive and phagocytic cells) from  various 
PECs by plastic adherence. The results in Fig.  1 indicate that positive binding by the 
AcM. 1 monoclonal antibody was noted on activated macrophages induced by pyran 
or C. parvum, whereas TGC-, PP-, or mineral oil-elicited macrophages were found to 
be negative. In addition, resident macrophages were also shown to be negative (data 
not  shown).  Thus,  the  results  indicated that  this  AcM. 1 monoclonal  antibody was 
specific for activated macrophages. 
Previous studies indicated that pyran and C. parvum are potent immunostimulants 
that  render  macrophages  tumoricidal  (18).  As  shown  in  Fig.  2,  it  is  evident  that 
tumoricidal capacity of macrophages was only associated with  pyran- or C. parvum- 
activated cells but not with TGC-elicited macrophages. To directly demonstrate that 
tumoricidal macrophages bear the AcM. 1 antigen, we treated pyran-activated PEC 
with the AcM. 1 monoclonal antibody or anti-Thy- 1 monoclonal antibody plus C  and 
then  tested  for  cytotoxicity against  tumor  cells.  Fig.  3  shows  that  pretreatment  of 
pyran-activated PEC  with the AcM. 1 antibody plus C  abolished ~80%  cytotoxicity 
against  tumor  cells.  However,  the  AcM. 1  antibody  only  or  antibody  plus  heat- 
inactivated (56°C  for 30 min)  C  and anti-Thy-1  monoclonal antibody, as expected, 
did not affect cytotoxicity of macrophages. Thus,  to our knowledge, this monoclonal 
antibody (AcM. 1) is the first unique marker of tumoricidal macrophages. TANIYAMA  AND  WATANABE  BRIEF  DEFINITIVE  REPORT  1289 
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Fxo.  1.  Expression of AcM. 1 antigen on pyran and C. parvum-activated  macrophages or thiogly- 
collate medium (TGCI)-,  proteose-peptone (PP)-, and mineral oil-elicited macrophages. Peritoneal 
macrophages purified from PEC of C3H/HeN  mice treated at day -8 with pyran  (25  mg/kg of 
body weight) or C. parvum (2.1 mg/mouse), or at day -4 with 10% TGC (1 ml/mouse), 10% PP (1 
ml/mouse), or  mineral  oil  (1  ml/mouse)  were mixed with  50 #1  of various  dilutions of AcM.1 
antibody in 96-well microtest plates, and then incubated for 1-2 h on ice. After washing twice with 
100 #1 of cold'PBS containing 2% BSA and 10 mM NAN3, the cells were further treated with 50 #1 
of lmI-labeled protein A (34,000  cpm/well) for 2-3 h on ice. After vigorous washing with cold PBS 
plus 2% BSA and  10 mM NAN3, each well was cut by scissors and counted in a  gamma counter. 
Each point represents the mean of triplicate wells. O, Pyran M~; m, c. parvum M~; A, TG(]  i~; 
V, PP MO; X, mineral oil-M~. 
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FIG.  2.  Macrophage-mediated cytotoxicity from  mice treated with pyran,  C  parvum, or TGC. 
Peritoneal exudate cells from mice treated at  -8 d  with pyran  (25  mg/kg of body weight) or C. 
parvurn (2.1  mg/mouse), or at -4 d  with 10% TGC  (1 ml/mouse), were harvested and adhered to 
plastic dishes.  After removing nonadherent  cells with  vigorous washings, adherent  cells  (>95% 
macrophages by  morphological  test)  were  recovered by  rubber  policeman  and  then  tested  for 
macrophage-mediated cytotoxicity against SlCr-labeled LI210 target cells (5 X 10  a cells/well). 0, C. 
paroum Mq,; m, Pyran Mq~; A, TGC M~. 1290  TANIYAMA AND WATANABE  BRIEF DEFINITIVE REPORT 
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FIo. 3.  Effect  of pretreatment of pyran-activated peritoneal exudate cells with AcM. 1 antibody 
and complement (C) on cytotoxicity against tumor cells. Pyran-activated PEC were treated with 
AcM.1 antibody  (1:1) and C  (A), monoclonal anti-Thy  1 antibody  (1:400) and C  (A), AcM.1 
antibody (1:1) and medium (F3), AcM. 1 antibody (1:1) and heat-inactivated C (m), medium and 
C (O), or medium for both incubation  (O), and then tested for tumor cytotoxicity against S]Cr- 
labeled LI210 target  cells that are insensitive to natural  killer (NK) lysis. Similar results were 
obtained by using C. parvum-activated PEC as effector cells. 
A  few years ago, Kaplan et al.  (12)  reported new cell surface antigens  (AMthCSA) 
on  activated  macrophages,  as  determined  by  a  heterologous  antiserum  adsorbed 
properly. The present study confirms the previous study and extends it by describing 
a  monoclonal antibody  (AcM. 1)  that  can discriminate  activated  macrophages from 
elicited  or  resident  macrophages.  However,  relationship  between  AcM.1  and 
AMthCSA has  not  been established  yet.  Our preliminary  experiment  indicates  that 
two  polypeptides  (67,000  and  44,000  mol wt)  are  identified  as  the  AcM. 1 antigen 
(unpublished  data).  Thus,  it  is  suggested  that  the  AcM.1  antigen  is  different  from 
Mac-l,2,3  (7,  8),  F4/80  (9,  10), and  2.6  (9,  10),  detected  by monoclonal antibodies 
and  membrane-associated  factor B  (19).  However,  further  investigation  is  necessary 
to determine whether the AcM. 1 antigen is an acquired product (such as complement 
component) or an endogenous macrophage product. 
In conclusion, all these data on the pattern  of reactivity strongly indicate that the 
AcM. 1 antigen  is a  new cell  surface  marker  for activated  tumoricidal  macrophages 
and  should  provide  a  useful  probe  to  investigate  the  mechanisms  of activation  of 
macrophages.  The  relationship  of this  AcM. 1 antigen  to  the  function  of activated 
macrophages and to other macrophage antigens is now under investigation. 
Summary 
New  activated  macrophage-specific  antigen  (AcM. 1)  detected  by  a  monoclonal 
antibody has been described.  The AcM. 1 antigen  was only detectable  on activated 
macrophages  induced  by  pyran  and  Corynebactrium parvum  but  not  on  resident  or 
thioglycollate  medium  (TGC),  proteose-peptone,  and  mineral  oil-elicited  macro- 
phages, and not on blood monocytes and neutrophils. 
Activated  macrophages  induced  by pyran  and  C. parvum,  as  expected,  exhibited 
tumor cytotoxicity, whereas TGC-elicited macrophages did not show any cytotoxicity. 
Moreover,  pretreatment  of pyran-activated  peritoneal  exudate  cells  with  AcM.1 
antibody plus complement abolished ~80% cytotoxicity. TANIYAMA AND WATANABE  BRIEF DEFINITIVE REPORT  1291 
Thus,  this AcM. 1 antigen  detected by a  monoclonal antibody is the first  unique 
marker of activated tumoricidal macrophages and should provide a  useful probe for 
investigating the mechanisms of activation or differentiation of macrophages. 
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Received  for publication 29 June 1982 and in revised  form 28 July 1982. 
References 
1.  Immunobiology of the iacrophages.  1976. D. Nelson, editor. Academic Press, New York. 
2.  Karnovsky, M. L., J. Leykins, D. Droth, and A. Harper.  1975. Biochemical characteristics 
of activated macrophages. Ann. N.  Y. Acad. Sci. 256:266. 
3.  Gordon, S., J. Todd, and Z. A. Cohn. 1974. In vitro synthesis and secretion of lysozyme by 
mononuclear phagocytes..]. Exp. Med.  139:1228. 
4.  Unkeless, J.  C.,  S.  Gordon, and  E.  Reich.  1974. Secretion of plasminogen activator by 
stimulated macrophages.J. Exp. Med.  139:834. 
5.  Wahl, L., S. M. Wahl, S. E. Mergenhargen, and G. R. Martin. 1975. Collagenae production 
of lymphokine-activated macrophages. Science (Wash.  D.  C.).  197:261. 
6.  Nathan, C. F., and R. K. Root.  1977.  Hydrogen peroxide release from mouse peritoneal 
macrophages. Dependence on sequential activation and triggering.J. Exp. Med.  146.'1648. 
7.  Springer, T.  A., G. Galfre, D.  S.  Secher, and  C.  Milstein.  1979.  Mac-l:  a  macrophage 
differentiation antigen identified by a monoclonal antibody. Eur. J. Immunol. 9:301. 
8.  Springer,  T.  A.  1980. Cell-surface  differentiation  in  the  mouse.  Characterization  of 
"Jumping" and "Lineage" antigens using xenogeneic rat monoclonal antibodies. In Mon- 
oclonal antibodies. R.  H.  Kennett, T. J.  McKearn, and  K. B.  Bechtol, editors. Plenum 
Press, New York.  185. 
9.  Austyn, J. M., and S. Gordon.  1981. F4/80, a  monoclonal antibody directed specifically 
against the mouse macrophage. Eur. J. ImmunoL 11:805. 
10.  Ezekowitz, R. A. B., Austyn, P. D. Stahl and S. Gordon. 1981. Surface properties of Bacillus 
Calmette-Gu6rin-activated mouse macrophages. Reduced expression of mannose-specific 
endocytosis, Fc receptors, and antigen F4/80 accompanies induction of Ia. J.  Exp.  Med. 
154:60. 
11.  Mellman, I. S., R. Steinman, J. C. Unkelss and Z. A. Cohn.  1980. Selective iodination and 
polypeptide composition of pinocytic vesicles.  J. Cell Biol. 86:712. 
12.  Kaplan, A. M., and T. Mohanakumar.  1977. Expression of a  new cell surface antigen on 
activated murine macrophages.ff. Exp.  Med.  146:1461. 
13.  Kaplan, A. M., H. D. Bear, L. Kirk, C. Cummins, and T. Mohanakumar.  1978. Relation- 
ship of expression of a  cell-surface antigen on  activated murine macrophages to tumor 
cytotoxicity.J. Immunol. 120:2080. 
14.  Kohler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature (Lond.). 256:495. 
15.  Gefter, M. C., D. H. Margulies, and M. D. Sharff.  1977. A simple method for polyethyl- 
eneglycol-promoted hybridization of mouse myeloma cells. Somat. Cell Genet. 3:231. 
16.  Bayer, E., and M. Wilchek. 1974. Insolubilized biotin for the purification ofavidin. Methods 
Enzymol. 34:365. 
17.  Taniyama, T., and H. T. Holden.  1979.  Cytolytic activity of macrophages isolated from 
primary routine sarcoma virus (MSV)-induced tumors. Int. ft. Cancer. 24:51. 
18.  Schultz, R. M., T. D. Papamattheeakis, J. Leutzeler, and M. A. Chirigos. 1977. Association 
of macrophage activation with antitumor activity by synthetic and biological agents. Cancer 
Res. 37:3338. 
19.  Yin, H. L., S. Aley, C. Bianco, and Z. A. Cohn.  1980. Plasma membrane polypeptides of 
resident and activated mouse peritoneal macrophages. Proc. Natl. Acad. Sci. U. S. A. 77:2188. 